GLP-1 targets beyond obesity, and misusing brain data

In this episode

First up on the podcast, people are buying consumer-grade brain wave detectors ostensibly to help with sleep, concentration, and meditation. But as freelance investigative journalist Jonathan Moens describes, companies are getting more than the price of the devices in the exchange—including training data for artificial intelligence models—in many cases without the consent of the user. Next on the show, we delve into the many uses for glucagonlike peptide-1 (GLP-1) agonist drugs beyond reducing obesity. Host Sarah Crespi talks with one of the special issue editors, Yevgeniya Nusinovich, senior editor at Science, about their potential for everything from improving cognition to combating cancer…